NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that Progyny’s Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 3:00 P.M. Pacific Time / 6:00 P.M. Eastern Time.
A live audiocast and replay will be available from the Events and Presentations section of Progyny’s website at http://investors.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women’s health and family building solutions, trusted by the nation’s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.
For Further Information, Please Contact:
Investors:
James Hart
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Alexis Ford
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$22.00 |
Daily Change: | 0.81 3.82 |
Daily Volume: | 1,606,632 |
Market Cap: | US$1.870B |
May 08, 2025 March 11, 2025 February 27, 2025 January 28, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load